Alimta® (pemetrexed) – Updated indication
January 31, 2019 - Eli Lilly announced the FDA approval of Alimta (pemetrexed), in combination with Keytruda® (pembrolizumab) and platinum chemotherapy, for the initial treatment of patients with metastatic, nonsquamous, non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.
Top